Gastrointestinal Cancer
Conditions
Brief summary
This is an open-label study to evaluate the safety and efficacy of an anticancer medication (A01) combined with immune cells (IC01) in subjects with advanced Gastrointestinal cancer.
Interventions
BIOLOGICALanticancer medication A01; immune cells IC01
The administration of the anticancer medication A01 and immune cells IC01 will be performed in The Second Hospital of Jiaxing, Zhejiang, China. The subjects will be observed for any side effects during this time and all the adverse events will be recorded.
Sponsors
The Second Hospital of Jia Xing
Hangzhou Converd Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Signed informed consent form must be obtained prior to any research procedures; 2. Age: 18 Years to 70 Years; 3. The patient's biological parent or child whose age ≥18 years voluntarily donates peripheral blood (200 ml) for the treatment, and who signs the informed consent form independently; 4. Histologically confirmed diagnosis of gastrointestinal cancer; 5. Patients who have received at least one standard treatment (surgery, chemotherapy, radiotherapy, or targeted therapy) or refuse to receive standard treatments; 6. Karnofsky Performance Status (KPS) score ≥ 70 7. Expected survival ≥ 3 months 8. Adequate organ function defined as: ANC≥3.5×10\^9/L, PLT≥50×10\^9/L, ALB≥25g/L, AST≤2.5×ULN, ALT≤2.5×ULN, TBIL≤1.5×ULN 9. If a subject is a female of childbearing potential, she must have a negative urine pregnancy test result.
Exclusion criteria
1. Patients who received chemotherapy, large-field radiotherapy or participated in other studies of anti-tumor therapy within 2 weeks before enrollment; 2. Patients who have not recovered from adverse reactions related to above-mentioned procedures; 3. Patients with two types of primary solid tumors; 4. Patients with brain metastases or bone metastases; 5. Patients with poorly controlled hypertension (systolic blood pressure \> 160 mmHg and/or diastolic blood pressure \> 90 mmHg), or cardiovascular and cerebrovascular diseases with clinical significance, such as cerebrovascular accident (within 6 months before signing informed consent), myocardial infarction (within 6 months before signing informed consent), unstable angina, congestive heart failure (New York Heart Association Class II or above), or severe arrhythmia which can't be controlled with drugs or have potential impact on treatment; 6. Patients with other serious organic diseases or mental disorders; 7. Patients with systemic or active infection; 8. Patients with positive HIV test result; 9. Patients who have received an organ transplant; 10. Patients who are breastfeeding or pregnant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The adverse events associated with infusion of the anticancer medication or the immune cells will be assessed. | Day 0 to 4 months after the end of the trial | Incidence and duration of all the adverse events will be recorded. The severity of adverse events will be evaluated according to NCI-CTCAE v4.03 criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tumor Response of the treatment in patients with advanced gastrointestinal cancer. | Before treatment and Day 28 to 4 months after the end of the treatment | Response Evaluation Criteria in Solid Tumors (RECIST) from the NCI will be used for assessment of radiographic response. |
Contacts
Primary ContactLin Chen, PhD
Outcome results
None listed